Kenvue has cut its annual sales forecasts on Thursday, since the consumer health company undergoes a strategic revision that aims to increase the brand’s performance in a cautious spending environment.The company, transformed by Johnson & Johnson in 2023, worked to support profitability, in particular in his unit of health and beauty in difficulty that hosts brands as neutrogenic and Aveno.
Wall Street analysts consider the manufacturer of patch as an acquisition objective after he was under pressure from investors, who criticized the unrelated services in those segments.
Kenvue has ousted his CEO Thibaut Mongon in July, that some investors expect would be the foundations for a possible sale of the whole company or of it. The company, which has appointed Kirk Perry as an interim garment, declared on Thursday that its previously announced strategic revision continues to advance and the Council is taking into consideration a wide range of potential alternatives.
He had also appointed former manager of Kellanova Amit Banati as a financial garment in May.Kenvue managers on a post-use call emphasized the exploitation of their previous experience in consumer companies to improve his performance to offer reliable and consistent results.
“I clearly see the opportunity in which I can intervene and make the difference immediately, drawing on my past experiences,” said Perry.
Tylenol manufacturer provides that its 2025 net sales decreased at low individual figures, compared to its previous expectations of an increase of 1% to 3%. He said that the cautious feeling of consumers was taken into consideration in the forecasts.
“Kenvue is clearly a” show me “story and must demonstrate a sequential improvement/a coherent delivery to allow actions to evaluate higher,” said analyst Nik Modi Nik Modi.
The company provides for an annual rectified profit to be between $ 1.00 and $ 1.05 per share, below the estimate of $ 1.13 analysts per share, according to data compiled by LSEG.
In the second quarter he recorded a rectified profit by action of 29 cents, compared to the estimate of 28 cents.
